Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q1- Text added to 2022 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
aggressive, Alabama, Anderson, Arm, August, Bayesian, bevacizumab, Birmingham, CBR, Colorectal, confirmed, CRC, defiance, disease, DOR, duration, efficacy, Endometrial, expand, expanded, inoperable, July, mCRPC, objective, OS, pembrolizumab, PR, primary, randomized, RECIST, Secondary, SOC, stable, unconfirmed, University, unresectable, variant
Removed:
gain, gastric, gastroesophageal, junction, utilize
Valuein 2022 Q1 filing- Value in 2022 Q2 filing
Original filings
Filing view